Connection

Co-Authors

This is a "connection" page, showing publications co-authored by FASIHA KANWAL and GEORGE CHOLANKERIL.
Connection Strength

9.994
  1. Inequalities in developing cirrhosis complications over time: A cohort study. Am J Gastroenterol. 2025 Feb 05.
    View in: PubMed
    Score: 0.998
  2. Reply to: "Transitioning FIB-4 score: From fibrosis screening tool to key biomarker for clinical endpoints". J Hepatol. 2024 Nov; 81(5):e230-e231.
    View in: PubMed
    Score: 0.960
  3. Unseen foe: The financial toxicity of liver transplantation. Liver Transpl. 2024 Sep 01; 30(9):873-874.
    View in: PubMed
    Score: 0.950
  4. Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 May; 80(5):e218-e219.
    View in: PubMed
    Score: 0.930
  5. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.855
  6. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
    View in: PubMed
    Score: 0.790
  7. NAFLD and HCC: Time to Bridge the Gap. Hepatology. 2021 11; 74(5):2336-2338.
    View in: PubMed
    Score: 0.786
  8. Temporal Changes in Risk Factors of Hepatocellular Carcinoma in a Prospective Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2024 Dec 16.
    View in: PubMed
    Score: 0.247
  9. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.245
  10. Beyond the baseline: Longitudinal surveillance with noninvasive tests for fibrosis in MASLD. Hepatology. 2024 Sep 23.
    View in: PubMed
    Score: 0.243
  11. Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
    View in: PubMed
    Score: 0.225
  12. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy. Liver Transpl. 2023 10 01; 29(10):1138-1142.
    View in: PubMed
    Score: 0.221
  13. Posttransplant outcomes for alcohol-associated liver disease during the COVID-19 pandemic. Liver Transpl. 2023 07 01; 29(7):777-780.
    View in: PubMed
    Score: 0.218
  14. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023 02 18; 76(4):592-599.
    View in: PubMed
    Score: 0.218
  15. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.215
  16. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.208
  17. Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplant Direct. 2022 May; 8(5):e1313.
    View in: PubMed
    Score: 0.205
  18. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2023 05; 21(5):1362-1364.e1.
    View in: PubMed
    Score: 0.204
  19. Clinical Factors Associated With Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients. Liver Transpl. 2022 01; 28(1):123-126.
    View in: PubMed
    Score: 0.200
  20. Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection. Liver Transpl. 2022 01; 28(1):127-130.
    View in: PubMed
    Score: 0.197
  21. Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. Transpl Int. 2021 Oct; 34(10):1971-1983.
    View in: PubMed
    Score: 0.197
  22. Early Impact of COVID-19 on Solid Organ Transplantation in the United States. Transplantation. 2020 11; 104(11):2221-2224.
    View in: PubMed
    Score: 0.186
  23. Racial and ethnic disparities in extended criteria allograft use for liver transplantation. Liver Transpl. 2025 Jan 29.
    View in: PubMed
    Score: 0.062
  24. Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials. Hepatology. 2025 Jan 28.
    View in: PubMed
    Score: 0.062
  25. The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure. J Hepatol. 2023 09; 79(3):717-727.
    View in: PubMed
    Score: 0.056
  26. Transplanting hepatitis B surface antigen-positive livers in the United States: Outcomes and opportunities. Am J Transplant. 2023 08; 23(8):1221-1226.
    View in: PubMed
    Score: 0.055
  27. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023 07 01; 78(1):179-194.
    View in: PubMed
    Score: 0.054
  28. Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
    View in: PubMed
    Score: 0.053
  29. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.052
  30. Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. Clin Transplant. 2022 06; 36(6):e14646.
    View in: PubMed
    Score: 0.051
  31. Marginal allografts in liver transplantation have a limited impact on length of stay. Clin Transplant. 2022 03; 36(3):e14544.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.